Last updated: February 7th, 2023

Study objective

The study SEMVAc investigates the safety and effectiveness of MVA-BN as part of the national vaccination campaign to make a valuable contribution to the worldwide management of mpox.
SEMVAc is a Germany-wide study led by Charité Universitätsmedizin in collaboration with practices, medical care centers and university hospitals.

Who can participate?

People who have received or will receive a vaccination and people who do not (initially) receive a vaccination can participate in this study. Whether you receive a vaccination does not depend on your participation in the study. Vaccination will be given as part of your routine medical care. If you participate and do not initially receive a vaccination, but in the future receive and accept a regular offer of vaccination, participation is of course still possible.

To better compare vaccinated individuals, we are still seeking individuals who fulfill the following criteria:

  • Age ≥18
  • Unvaccinated or upcoming vaccination with MVA-BN smallpox vaccine
  • Men and trans* persons who have sex with men (MSM) and/or trans* persons
  • No known mpox disease
  • Resident in Berlin

How does the study work?

  • Duration: 12 months
  • Inclusion interview in doctor’s office (approx. 10min)
  • Monthly online surveys (approx. 3-5min)

What’s your benefit?

  • At least 10€ compensation per quarterly routine visit in your treating physician’s office
  • Important contribution to research on monkeypox management and vaccination

Interested? Write us a short e-mail here.

The following map shows confirmed (green) and planned (yellow) study sites.